Heart failure and chronic obstructive pulmonary disease: a review

Area of Science:

• Cardiology
• Pulmonology
• Internal Medicine

Background:

• Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are leading causes of global morbidity and mortality.
• These conditions share risk factors (smoking, age, inflammation) and overlapping symptoms (dyspnea, cough, exercise intolerance), making differential diagnosis challenging.
• The co-existence of HF and COPD significantly impacts exercise capacity and quality of life.

Purpose of the Study:

• To highlight the diagnostic challenges in differentiating COPD exacerbations from HF decompensation.
• To review the utility of natriuretic peptides and echocardiography in HF diagnosis.
• To outline optimal treatment strategies for patients with comorbid HF and COPD.

Main Methods:

• Review of diagnostic criteria and clinical presentation of HF and COPD.
• Discussion of natriuretic peptide levels (BNP, NT-proBNP) for HF exclusion.
• Emphasis on echocardiography as the gold standard for HF imaging.
• Analysis of evidence-based pharmacotherapy for combined HF and COPD management.

Main Results:

• Natriuretic peptides are sensitive HF biomarkers, with established cut-off values for exclusion (BNP <100 pg/mL, NT-proBNP <300 pg/mL).
• Echocardiography is essential for confirming HF diagnosis.
• Combined HF and COPD necessitates specific drug classes, including ACE inhibitors, ARBs, beta-blockers, aldosterone antagonists, and long-acting bronchodilators.

Conclusions:

• Accurate diagnosis of coexisting HF and COPD is critical due to worse prognosis compared to single-disease states.
• Integrated management requires careful monitoring of cardiopulmonary function.
• Multidisciplinary approaches are essential for optimizing patient outcomes.